Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
Summary
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals and now owns the company outright. The deal adds KalVista’s hereditary angioedema treatment, EKTERLY, to Chiesi’s rare disease portfolio. KalVista’s shares have stopped trading on Nasdaq after the merger closed. The announcement also highlights ongoing regulatory work and expansion plans for EKTERLY in additional markets and pediatric patients.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected